A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis (NCT06869551)

🧪 Interventions in This Study

• Deucravacitinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (47 Sites)

Showing the first 25 of 47 sites.

• Local Institution - 0038 — Lancaster, California
• Local Institution - 0020 — Chicago, Illinois
• Local Institution - 0023 — Indianapolis, Indiana
• Local Institution - 0059 — North New Hyde Park, New York
• Local Institution - 0065 — Cincinnati, Ohio
• Local Institution - 0066 — Cleveland, Ohio
• Local Institution - 0036 — Austin, Texas
• Centro de Oncologia Leonardo Da Vinci - ATO Terapias — Fortaleza, Ceará
• Local Institution - 0032 — Cuiabá, Mato Grosso
• Santa Casa de Misericordia de Belo Horizonte — Belo Horizonte, Minas Gerais
• Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância — Curitiba, Paraná
• Local Institution - 0013 — Curitiba, Paraná
• Hospital Das Clinicas Ufpe — Recife, Pernambuco
• Local Institution - 0033 — Porto Alegre, Rio Grande do Sul
• LMK Serviços Médicos S/S — Porto Alegre, Rio Grande do Sul
• PSEG- Pesquisa Clínica — Vila Clementino, São Paulo-SP
• Local Institution - 0027 — Rio de Janeiro,
• Santa Casa Instituto de Pesquisa — São Paulo,
• Local Institution - 0010 — São Paulo,
• University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD — Plovdiv,
• Local Institution - 0069 — Sofia,
• Local Institution - 0062 — Sofia,
• Local Institution - 0074 — Beijing, Beijing Municipality
• Local Institution - 0049 — Beijing, Beijing Municipality
• The Children's Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Juvenile Psoriatic Arthritis

• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis — Rosario, Santa Fe Province
• Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). — Loma Linda, California
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab — Little Rock, Arkansas

Explore by condition: All Juvenile Psoriatic Arthritis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.